Showing 1 - 12 results of 12 for search 'Zhiling Yan', query time: 0.04s
Refine Results
-
1
-
2
-
3
-
4
Design and evaluation of a multi-epitope DNA vaccine against HPV16 by Lanfang Zhu, Xiangjie Cui, Zhiling Yan, Yufen Tao, Lei Shi, Xinwen Zhang, Yufeng Yao, Li Shi
Published 2024-12-01
Article -
5
Cleft lip and palate transmembrane protein 1-like is a putative regulator of tumorigenesis and sensitization of cervical cancer cells to cisplatin by Weipeng Liu, Fengdan Huang, Yueting Yao, Yan Liang, Zhiling Yan, Lili Guo, Xinwen Zhang, Li Shi, Yufeng Yao
Published 2024-09-01
Article -
6
-
7
Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells by Yanyan Lu, Yanyan Lu, Yanyan Lu, Hong Zhu, Hong Zhu, Hong Zhu, Yang Liu, Yang Liu, Yang Liu, Ying Wang, Ying Wang, Ying Wang, Yinxiang Sun, Yinxiang Sun, Yinxiang Sun, Hai Cheng, Hai Cheng, Hai Cheng, Zhiling Yan, Zhiling Yan, Zhiling Yan, Jiang Cao, Jiang Cao, Jiang Cao, Wei Sang, Wei Sang, Wei Sang, Feng Zhu, Feng Zhu, Feng Zhu, Depeng Li, Depeng Li, Depeng Li, Haiying Sun, Haiying Sun, Haiying Sun, Junnian Zheng, Junnian Zheng, Junnian Zheng, Kailin Xu, Kailin Xu, Kailin Xu, Zhenyu Li, Zhenyu Li, Zhenyu Li
Published 2023-05-01
Article -
8
The prognostic significance of POD24 in peripheral T-cell lymphoma by Huimin Chen, Ruixue Ma, Qianqian Zhang, Fengyi Lu, Yuhan Ma, Jingxin Zhou, Jiang Cao, Kunming Qi, Zhiling Yan, Wei Sang, Feng Zhu, Haiying Sun, Depeng Li, Zhenyu Li, Hai Cheng, Kailin Xu, Wei Chen
Published 2024-12-01
Article -
9
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation by Cheng Zhang, Xiaoqi Wang, Hai Yi, Yi Wang, Zhiling Yan, Jian Zhou, Ting Yang, Aibin Liang, Zhen Wang, Yingying Ma, Qin Wen, Lei Gao, Li Gao, Peiyan Kong, Xu Tan, Erlie Jiang, Xi Zhang
Published 2024-10-01
Article -
10
A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells by Yang Liu, Yang Liu, Yang Liu, Xingxing Jie, Xingxing Jie, Xingxing Jie, Li Nian, Li Nian, Li Nian, Ying Wang, Ying Wang, Ying Wang, Congyue Wang, Congyue Wang, Congyue Wang, Jin Ma, Jin Ma, Jin Ma, Jingjing Jiang, Jingjing Jiang, Jingjing Jiang, Qingyun Wu, Qingyun Wu, Qingyun Wu, Jianlin Qiao, Jianlin Qiao, Jianlin Qiao, Wei Chen, Wei Chen, Wei Chen, Jiang Cao, Jiang Cao, Jiang Cao, Zhiling Yan, Zhiling Yan, Zhiling Yan, Ming Shi, Hai Cheng, Hai Cheng, Hai Cheng, Feng Zhu, Feng Zhu, Feng Zhu, Wei Sang, Wei Sang, Wei Sang, Depeng Li, Depeng Li, Depeng Li, Chong Chen, Chong Chen, Chong Chen, Kailin Xu, Kailin Xu, Kailin Xu, Zhenyu Li, Zhenyu Li, Zhenyu Li
Published 2023-04-01
Article -
11
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial by Ming Shi, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Junnian Zheng, Jiang Cao
Published 2024-04-01
Article -
12
Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma by Wei Sang, Ming Shi, Jingjing Yang, Jiang Cao, Linyan Xu, Dongmei Yan, Meixue Yao, Hui Liu, Weidong Li, Bing Zhang, Kemeng Sun, Xuguang Song, Cai Sun, Jun Jiao, Yuanyuan Qin, Tingting Sang, Yuanyuan Ma, Mei Wu, Xiang Gao, Hai Cheng, Zhiling Yan, Depeng Li, Haiying Sun, Feng Zhu, Ying Wang, Lingyu Zeng, Zhenyu Li, Junnian Zheng, Kailin Xu
Published 2020-08-01
Article